Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream

    July 2022 in “ Clinical Cosmetic and Investigational Dermatology ”
    Carol M. Sánchez, Jonette Keri
    Studysummary This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on dovepress.com →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Efficacy, Tolerability, and Safety of Montelukast Versus Finasteride for the Treatment of Moderate Acne in Women: A Prospective, Randomized, Single-Blinded, Active-Controlled Trial Journal of Cosmetic Dermatology · 2021
    2. Clascoterone as a Novel Treatment for Androgenetic Alopecia Clinical and Experimental Dermatology · 2020
    3. The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study American Journal of Clinical Dermatology · 2018
    4. A Review of Hormone-Based Therapies to Treat Adult Acne Vulgaris in Women International Journal of Women's Dermatology · 2017
    5. Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist Drug Research · 2011
    6. A Comparison of the Relative Efficacy of Antiandrogens for the Treatment of Acne in Hyperandrogenic Women Clinical Endocrinology · 2002